XML 26 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation Arrangements
 12 Months Ended
Dec. 31, 2011
Stock-Based Compensation Arrangements  
Stock-Based Compensation Arrangements

11             Stock-Based Compensation Arrangements

 

ASC 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period, which for the Company is the period between the grant date and the date the award vests or becomes exercisable. Most of the awards granted by the Company (and still outstanding), vest ratably over four years, with ¼ of the award vesting one year from the date of grant and 1/48 of the award granted vesting each month thereafter.  Annual awards granted in December 2010 vest 1/48 of the award each month after the grant date. Certain awards made to executive officers vest over three to five years, depending on the terms of their employment with the Company.

 

The Company recognizes all share-based awards issued after the adoption of ASC 718 under the straight-line attribution method.  ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company evaluates its forfeiture assumptions quarterly and the expected forfeiture rate is adjusted when necessary.  Ultimately, the actual expense recognized over the vesting period is based on only those shares that vest.

 

Stock based compensation has been reported within expense line items on the consolidated statement of operations for 2009, 2010 and 2011 as shown in the following table:

 

 

 

Year ended
December 31,
2009

 

Year ended
December 31,
2010

 

Year ended
December 31,
2011

 

 

 

$000

 

$000

 

$000

 

Research and development

 

271

 

351

 

171

 

Selling, general and administrative

 

539

 

1,395

 

711

 

Stock-based compensation costs before income taxes

 

810

 

1,746

 

882

 

 

2006 Plans

 

On March 16, 2006, Xcyte stockholders approved the adoption of the 2006 Plans, under which Cyclacel, may make equity incentive grants to its officers, employees, directors and consultants. On May 14, 2008, at the Company’s annual stockholders meeting, the stockholders increased the number of shares reserved under the 2006 Plans to 5.2 million shares of common stock from 3.0 million shares of common stock.

 

During 2011, the Company granted approximately 0.2 million options to employees and directors with a grant date fair value of approximately $0.2 million, of which approximately $24,000 has been recorded as compensation cost in the consolidated statement of operations for the year ended December 31, 2011.  During 2010, the Company granted approximately 0.6 million options to employees and directors with a grant date fair value of approximately $0.6 million, of which approximately $50,000 was expensed in 2010. During 2009, the Company granted approximately 0.2 million options to employees and directors with a grant date fair value of $0.1 million, of which approximately $28,000 was expensed in 2009.  The weighted average grant-date fair value of options granted during 2011, 2010, and 2009 was $1.15, $1.40 and $0.39, respectively.

 

As of December 31, 2011, the total remaining unrecognized compensation cost related to the non-vested stock options amounted to approximately $0.5 million, which will be amortized over the weighted-average remaining requisite service period of 2.88 years.

 

During the years ended December 31, 2009, 2010 and 2011, the Company did not settle any equity instruments with cash.

 

The Company received $3,000 from the exercise of 6,638 stock options during 2011.  The total intrinsic value of options exercised during 2011 was approximately $1,000.  The Company received approximately $0.1 million from the exercise of 174, 311 stock options during 2010.  The total intrinsic value of options exercised during 2010 was approximately $0.2 million.  The Company received $7,000 from the exercise of 17,180 options during 2009.  The total intrinsic value of options exercised during 2009 was approximately $11,000.

 

Outstanding Options

 

A summary of the share option activity and related information is as follows:

 

Cyclacel Pharmaceuticals, Inc.

 

Number of
options
outstanding

 

Weighted
average
exercise
price

 

Weighted
average
remaining
contractual
term (years)

 

Aggregate
intrinsic
value

 

Options outstanding at December 31, 2009

 

3,349,876

 

$

4.21

 

7.76

 

$

698

 

Granted

 

607,300

 

$

1.82

 

 

 

 

 

Exercised

 

(174,311

)

$

0.43

 

 

 

 

 

Cancelled/forfeited

 

(292,933

)

$

4.54

 

 

 

 

 

Options outstanding at December 31, 2010

 

3,489,932

 

$

3.96

 

7.22

 

$

938

 

Granted

 

199,500

 

$

1.52

 

 

 

 

 

Exercised

 

6,638

 

$

0.41

 

 

 

 

 

Cancelled/forfeited

 

167,053

 

$

5.79

 

 

 

 

 

Options outstanding at December 31, 2011

 

3,515,741

 

$

3.73

 

6.44

 

$

140

 

Unvested at December 31, 2011

 

631,655

 

$

1.73

 

8.75

 

$

3

 

Vested and exercisable at December 31, 2011

 

2,884,086

 

$

4.17

 

5.93

 

$

136

 

 

The following table summarizes information about options outstanding at December 31, 2011:

 

Exercise price ($)

 

Number
outstanding

 

Weighted
Average
remaining
contractual life

 

Number
exercisable

 

0.29 — 1.98

 

1,519,913

 

7.77

 

1,013,387

 

2.15 — 4.95

 

377,878

 

7.15

 

256,989

 

5.26 — 5.81

 

508,213

 

5.82

 

503,973

 

6.30 — 6.95

 

891,237

 

4.57

 

891,237

 

7.80 — 15.00

 

218,500

 

4.93

 

218,500

 

 

 

3,515,741

 

 

 

2,884,086

 

 

The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the following assumptions:

 

 

 

Year ended
December 31,
2009

 

Year ended
December 31,
2010

 

Year ended
December 31,
2011

 

Expected term (years)

 

0.75 — 5 Yrs

 

5 — 6 Yrs

 

5 — 6 Yrs

 

Risk free interest rate

 

0.325 — .84%

 

1.64 — 2.96%

 

1.47 — 2.29%

 

Volatility

 

65 — 169%

 

90 — 102%

 

93 — 99%

 

Dividends

 

0.00%

 

0.00%

 

0.00%

 

 

 

 

Year ended
December 31,
2009

 

Year ended
December 31,
2010

 

Year ended
December 31,
2011

 

Resulting weighted average grant date fair value

 

$

0.39

 

$

1.40

 

$

1.15

 

 

The expected term assumption was estimated using past history of early exercise behavior and expectations about future behaviors. Starting with the December 2010 annual grants to the Company’s employees, the Company relied exclusively on its historical volatility as an input to the option pricing model as management believes that this rate will be representative of future volatility over the expected term of the options.  Before December 2010, due to the Company’s limited existence of being a public company, the expected volatility assumption has been based on the historical volatility of peer companies over the expected term of the option awards.

 

Estimates of pre-vesting option forfeitures are based on the Company’s experience. Currently the Company uses a forfeiture rate of 0 — 50% depending on when and to whom the options are granted. The Company adjusts its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment in the period of change and may impact the amount of compensation expense to be recognized in future periods.

 

The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. During the years ended December 31, 2009, 2010 and 2011, the Company recognized income of $0.5 million, an expense of $0.5 million, and an expense of approximately $38,000, respectively, as a result of revised forfeiture rates.

 

The weighted average risk-free interest rate represents interest rate for treasury constant maturities published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option.

 

The Company received approximately $3,000 from the exercise of 6,638 options during 2011. The Company received approximately $0.1 million from the exercise of 174,311 options during 2010. No income tax benefits were recorded because ASC 718 prohibits recognition of tax benefits for exercised stock options until such benefits are realized. As Cyclacel incurred tax losses in 2010 and 2011, the Company was not able to benefit from the deduction for exercised stock options in the current reporting period.

 

Related to the workforce reduction in the second and third quarters of 2009, the Company amended the exercise period in which the employees would be able to exercise their vested stock options from thirty (30) days post termination date to nine months. In addition, the Company allowed the individuals to continue to vest stock options until November 18, 2009 as if they were still employed in recognition of past work. In accordance with ASC 718, the Company considered this a Type III modification and thus recorded stock-based compensation expense of $0.3 million during the second and third quarters of 2009.

 

Restricted Stock

 

In November 2008, the Company issued 50,000 shares of restricted common stock to an employee subject to certain forfeiture provisions.  Specifically, one quarter of the award vests one year from the date of grant and 1/48 of the award effectively vests each month thereafter.  This restricted stock grant was accounted for at fair value at the date of grant and an expense is recognized during the vesting term. As of December 31, 2011, the total remaining unrecognized compensation cost related to the non-vested restricted stock amounted to approximately $3,000, which will be amortized over the weighted-average remaining requisite service period of 0.88 years. Summarized information for restricted stock activity for the years ended December 31, 2010 and 2011 is as follows:

 

 

 

Restricted Stock

 

Weighted Average Grant
Date Value Per Share

 

Non-vested at December 31, 2009

 

36,458

 

$

0.44

 

Vested

 

(12,504

)

$

0.44

 

Non-vested at December 31, 2010

 

23,954

 

$

0.44

 

Vested

 

(12,504

)

$

0.44

 

Non-vested at December 31, 2011

 

11,450

 

$

0.44

 

 

Restricted Stock Units

 

The Company issued 91,700 and 238,000 restricted stock units each of which entitles the holders to receive a share of the Company’s common stock, to senior executives of the Company in November 2008 and December 2011, respectively. The 2008 grants vest over four years and the 2011 grants vest over three years.  A restricted stock unit grant is accounted for at fair value at the date of grant which is equivalent to the market price of a share of the Company’s common stock, and an expense is recognized over the vesting term. As of December 31, 2011, the total remaining unrecognized compensation cost related to non-vested restricted stock amounted to approximately $0.1 million, which will be amortized over the weighted-average remaining requisite service period of 2.78 years. In December 2011, the Company issued restricted stock units to senior executives of the Company. Summarized information for restricted stock units activity for the years ended December 31, 2010 and 2011 is as follows:

 

 

 

Restricted Stock Units

 

Weighted Average Grant
Date Value Per Share

 

Non-vested at December 31, 2009

 

54,687

 

$

0.44

 

Vested

 

(18,756

)

$

0.44

 

Non-vested at December 31, 2010

 

35,931

 

$

0.44

 

Granted

 

238,000

 

$

0.83

 

Vested

 

(18,756

)

$

0.44

 

Non-vested at December 31, 2011

 

255,175

 

$

0.80